Kowa Company, Ltd. traces its founding to 1894 as a Japanese cotton fabric wholesaler and now operates across textiles, machinery, medicines, medical devices and vision units, according to its corporate profile. Within that group, the Chofu Factory appears in FDA records as the applicant for the KOWA FM-600, a laser flare meter filed under the ophthalmic laser scanning ophthalmoscope regulation. The record set covers one 510(k) submission and an earlier clearance for the same trade name, which together frame the documented device identity and the technical changes described in the recent review. [1][2][8][9]
The Chofu Factory applicant and its FDA record
FDA records identify Kowa Company, Ltd. Chofu Factory as the applicant on K261255, with a filing address of 3-1 Chofugaoka 3-Chome, Chofu, Tokyo 182-0021, Japan. The submission was received April 16, 2026, and decided September 11, 2026, with decision code SESE, described as substantially equivalent, under a traditional clearance type and the ophthalmic advisory committee. The correspondence for the same submission is addressed to the applicant care of a regulatory consultant in Tokyo. The filing address is an FDA record entry and does not establish a corporate headquarters. [1][2]
The supplied collection contains one linked 510(k) record, and its decision count is one SESE. The smaller record sample likewise contains that single entry, K261255. These figures describe the filings assembled for this profile as of the snapshot date; they are not measures of company sales, total portfolio or safety performance. [1]
KOWA FM-600 device identity and components
The device is filed as Kowa Fm-600 under regulation number 21 CFR 886.1570, regulation name Ophthalmoscope, regulatory class II, product code MYC, with the classification name Ophthalmoscope, Laser, Scanning and an ophthalmic medical specialty. The FDA letter dates the submission August 5, 2026, and records receipt August 6, 2026. Kowa’s own product pages list the FM-600 under laser flare meters, with model number LSS50AK. [2][5][6]
Published specifications from Kowa Pharmaceuticals America describe a measuring laser source of a 635 nm laser diode at 35±15 μw, a photo-multiplier tube detector, a measuring range of 1 to 500 photon count per millisecond, and a measuring field of 0.3 mm vertical. The same publisher describes the FM-600 as upgraded for measurement of aqueous flare in the anterior chamber, with a front view alignment mode. These are manufacturer-published product descriptions, not clinical findings. [5][6]
What changed relative to the earlier clearance
An earlier 510(k) summary, prepared August 4, 2009, identifies the same trade name, KOWA FM-600, under 21 CFR 886.1570 and product code MYC, and names the Laser flare meter FM-500 as the predicate device. That summary was submitted by Kowa Company, Ltd. from its Electronics & Optics Division address in Chuo-ku, Tokyo, a different address from the Chofu Factory entry in the 2026 record. [8]
The 2026 review correspondence includes a comparison table listing a MEMS mirror in place of a galvanometer, marked as changed from galvanometer to MEMS mirror, and an alignment mode listed as front view alignment against side view alignment, marked different. The table is the documented basis for describing those two elements as changes; it does not establish performance results. [2]
Corporate context and scope limits
Kowa’s corporate profile states the group was founded December 25, 1894, as a cotton fabric wholesaler and has grown into a global enterprise with a 130-year history, with businesses spanning textile, machinery and construction materials trading alongside medicines, medical devices, vision units and energy-related products. That profile describes the Kowa Company, Ltd. group; it does not state that the Chofu Factory is a separate legal entity or identify a parent of the applicant beyond the naming in FDA records. [9]
Kowa’s product listings place the FM-600 alongside the FM-700 within its laser flare meter line, and the FDA record for K261255 covers the FM-600 only. No recall records appear in the assembled collection, and no conclusion about commercial availability in any market, certification or comparative performance follows from these filings. [1][4][5]
